TEAM
Liza Velarde • Co Founder, Director & CEO
Read More
Alejandro Abarca • Co Founder, Director & CTO
Read More
Juan Felipe Yee • Co Founder, Director & CMO
Read More
Reasons to Invest
- Blood-based assay for the early detection of cancer and monitoring of the applied treatments’ effectiveness, which is enabled by two independent devices created to effectively isolate and analyze circulating tumor cells (CTCs). Delee has a fully functional technology that is being successfully tested for prostate and breast cancer with pre-orders worth a potential value of over $2.5 million USD.
- Delee is backed by Y Combinator and StartX, and has raised over $2.4 million USD in funding. In 2020, the global circulating tumor cell market was valued at $8.4 billion USD, and it is expected to reach $18.3 billion USD by 2027.
- We have built an experienced team of specialists in the fields of molecular biology, electronics, artificial intelligence, clinical oncology, product design, and manufacture.
*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.
Since our last raise
Milestones Reached
- We improved the capabilities of our previous prototypes to greatly increase the robustness and reliability of our CTC blood-based assay.
- We completed the commercial versions of the devices that enable the CTC blood-based assay.
- We expanded the number of collaborations with medical institutions, which will allow us to clinically validate our technology in less time.
- We increased the number of processed patient samples to assess the feasibility of using our technology for various cancer-related clinical applications.
- We expanded our team in order to accelerate the commercial launch of our technology.
*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.
The Problem
* Source
Cancer has become a major global health issue. According to the International Agency for Research on Cancer (IARC), in 2020, the number of new registered cases surpassed 19.2 M globally, whereas over 9.9 M deaths occurred due to this disease (Source). Despite all the recent breakthroughs in cancer treatments, it is estimated that by 2040, the number of new registered cases and fatalities per year will increase to 30.2 M and 16.3 M, respectively (Source, Source). The National Cancer Institute (NCI) estimates that 39.5% of Americans will be diagnosed with cancer at some point during their lifetime (Source), unfortunately, many of these people will lose their lives because of it. One of the main reasons cancer has such a high mortality rate is due to the current lack of tests with the required sensitivity and specificity to enable an early diagnosis of the disease.
When it comes to cancer, the detection of tumors at an early stage is key because the survival rate in most types of cancer is directly related to the stage at which tumors are detected. For example, the 5-year relative survival rate for breast cancer when detected at early stages is 99%, but drops to 28% when detected at late stages (Source). Furthermore, early detection has the potential to reduce the financial burden of health care on individuals and public health services mainly because cancer treatments used for treating localized disease are less complex, and therefore, less expensive; according to the World Health Organization (WHO), studies made in high-income countries have shown that the cost of cancer treatment, when detected at early stages, is 2 to 4 times less expensive than at advanced stages (Source).
Moreover, there is a lack of technological resources to provide effective monitoring of the applied cancer treatments’ efficacy, which may significantly reduce the patients’ chances of survival given that the right treatment at the right time for each cancer patient may not be administered due to the lack of information available for physicians.
Since there is an unmet need for tests that can reliably detect cancer at early stages and monitor the applied treatments’ effectiveness, the research community has been actively searching for novel biomarkers that can provide clinical information for these purposes. The isolation of circulating tumor cells (CTCs) from blood is a recent alternative that could address this need. In the last decade, CTCs have attracted a significant amount of attention for their potential use as a blood-based biomarker for a broad range of cancer-related clinical applications. CTCs are malignant cells that are shed from the primary and/or metastatic solid tumors that infiltrate into the vascular and lymphatic systems; these cells play a fundamental role in the metastatic process of non-hematological cancers (Source, Source).
Technologies that detect and isolate CTCs from blood can be used to develop assays that could enable early cancer detection and monitor the applied treatments’ effectiveness. However, the isolation of these malignant cells from blood represents a major technological challenge due to their heterogeneity and extremely low numbers in comparison to blood cells (Source, Source); on average, you can find around 40.5 billion cells in 7.5 mL of blood, while a cancer patient may have between 1 and 1000 CTCs in the same volume (Source).
Even though there currently exists multiple cell sorting methods, such as fluorescent-activated cell sorting, magnetic-activated cell sorting, fluorescent-activated droplet sorting, and density gradient centrifugation, these are not compatible with whole blood samples and/or do not have the sufficient sensitivity and specificity to correctly isolate CTCs from blood, which have prevented the development of assays with potential clinical utility... until now.
Our Solution
At Delee, we have created the CytoCatch™ isolation platform and imaging system. These units enable the performance of a CTC blood-based assay that has the potential of being used for early cancer detection and monitoring of the applied treatments’ effectiveness, allowing the optimization of each patient’s therapy throughout the course of the disease.
*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.
How it works
For the assay, a single blood tube is extracted by conventional venipuncture (the collection method that is usually used for laboratory testing). The blood sample along with several reagents are loaded on the CytoCatch™ isolation platform, which automatically performs the necessary steps to prepare and process the sample, capturing the contained CTCs. The unit has an outstanding performance, it has recovery rates above 94% when processing 7.5 mL blood samples spiked with tumor cells from prostate, breast, and colorectal cancer cell lines, meaning that the platform recovers at least 94 out of 100 tumor cells spiked into the sample (Source).
Once captured, the CytoCatch™ isolation platform executes an automated protocol to stain the collected cells with fluorescent antibodies for their further analysis with the CytoCatch™ imaging system, which possesses special routines and machine learning algorithms that analyze the captured cells based on their morphology and the expression of specific markers. The fact that all these processes are fully automated increases the reliability and reproducibility of the assay by preventing human error and cell loss due to manual steps.
Furthermore, the collected cells are compatible with traditional molecular biology techniques and next generation sequencing technologies, enabling the performance of molecular analyses to assess the genetic characteristics of the captured CTCs. Finally, the treating physician will get a report with the corresponding results.
*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.
ONCOLOGICAL CLINICAL APPLICATIONS
Our technology has the specificity and sensibility required to successfully isolate and analyze CTCs from blood, which may enable the following clinical applications:
*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.
BENEFITS OF OUR TECHNOLOGY
The early detection of cancer and the monitoring of the applied treatments’ effectiveness will be translated into invaluable benefits for patients and their families, being the most important, and the main reason for all our work, to greatly increase their chances of defeating cancer. Furthermore, monitoring the treatments’ effectiveness could also significantly increase the odds of defeating cancer by applying the most effective treatment for each patient throughout the course of the disease, while reducing the incurred costs and the negative side effects caused by drugs that wouldn’t be effective for a particular patient.
FOR WHAT TYPES OF CANCER?
Our technology can be used for a wide variety of cancer types. There is scientific evidence that indicates the feasibility of developing CTC assays to enable clinical applications in various types of cancer, including prostate, breast, colorectal, lung, cervical, skin, and ovarian cancer, just to name a few. Prostate, breast, colorectal, and lung cancer are responsible for over 40% of new cancer cases and a third of the deaths registered worldwide due to this disease (Source).
Traction
Pre-orders worth a potential value of over $2.5 million USD
We’ve gotten great traction since the pre-commercial launch of our technology. To date, pre-orders worth a potential value of over $2.5 million USD have been secured from research centers of various hospitals in order to use our technology as an in vitro diagnostic platform for research use only, prior to FDA clearance.
Customers
Who buys it?
Prior to acquiring FDA clearance, Delee aims to commercialize the CytoCatch™ isolation platform and imaging system as research tools, being pharmaceutical companies and research centers our main customers. Once our technology obtains FDA clearance, it will be commercialized as an in vitro diagnostic medical device for hospitals and laboratories.
Business Model
Recurring revenue through consumable and reagent sales
Prior to FDA clearance, our devices will be commercialized as research tools, where the razor and blades business model will be followed, obtaining recurrent revenue by selling the necessary reagents and consumables to perform each test. This model will be maintained once FDA gives clearance for our technology to be commercialized as an in vitro diagnostic medical device for hospitals and laboratories.
*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.
Market
An $18.3 billion USD market by 2027
According to a recent report published by Grand View Research, in 2020, the global circulating tumor cell market was valued at $8.4 billion USD, and it’s expected to reach an $18.3 billion USD valuation by 2027 (Source, Source). This growth is mainly driven by the increase in the number of cancer cases that will occur in the coming years.
At Delee, we are initially validating our technology for prostate and breast cancer, to later expand it to lung and colorectal cancer, mainly because, in 2020 alone, these four types of cancer account for over 40% of the new cancer cases registered worldwide and were responsible for over 3.7 million deaths (Source).
Competitors
A more effective way to capture and analyze CTCs
Most of the blood tests employed as auxiliaries in the diagnosis of cancer and monitoring of the applied treatments’ effectiveness measure protein tumor markers levels, such as PSA, CA-125, and AFP. However, there are only a few protein tumor markers that are associated with a particular cancer and are clinically useful; most types of cancer have not been linked to an increase in the levels of a particular protein tumor marker (Source). Furthermore, these types of tests have a poor sensitivity and specificity, meaning that these markers may be elevated in people that do not have cancer and that not every person with a particular type of cancer will have an elevated level of the corresponding tumor marker (Source). Taking the PSA test as an example, which measures the amount of PSA in blood and is used to screen for prostate cancer, approximately 66% of men with increased levels of PSA do not have prostate cancer, whereas over 15% of the men with normal levels of PSA may have prostate cancer (Source).
The isolation and analysis of CTCs is a relatively new practice, and physicians are starting to recognize all its potential benefits. Most of the current CTCs technologies, including the CellSearch® System, which is considered the gold standard, rely on the existence of specific proteins on the tumor cell membrane in order to capture them. However, CTCs are incredibly heterogeneous; when entering the bloodstream, they undergo a biological process that downregulates these proteins, limiting the efficiency with which these cells are captured and thereby losing valuable information (Source, Source). Our technology changes the norm by isolating CTCs irrespective of the proteins expressed in their membranes, allowing us to capture tumor cells that other technologies simply can’t.
*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.
Our Vision
(or click)
(or click)
(or click)
(or click)
ABOUT
HEADQUARTERS
1211 San Dario Ave #2068
Laredo, TX 78040
WEBSITE
View Site
TERMS
Overview
PRICE PER SHARE
DEADLINE
Apr. 3, 2025 at 6:29 AM UTC
VALUATION
Breakdown
MIN INVESTMENT
MAX INVESTMENT
OFFERING TYPE
Maximum Number of Shares Offered subject to adjustment for bonus shares
ALL UPDATES
04.07.22
The final 6 hours to become an investor in Delee!
The campaign is 6 hours away from finishing. Thank you for your support and your feedback during our SE campaign.
If you reserved during the TTW stage this is your last chance to confirm your investment to get your bonus share, and to all the people interested in investing, here are some of the reasons why we think you should.
CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.
Delee is backed by Y Combinator, StartX, and Emles Venture Partners.
The founders have a scientific background and more than 10 years of experience developing scientific instrumentation.
Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,
Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required.
To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center.
The TAM for the use of CTCs in clinical applications is calculated at over $543B.
We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.
Thanks to all investors for believing in our vision and for making it a reality.
Delee Team 💙
04.06.22
The final 12 hours to become an investor in Delee!
The campaign is 12 hours away from finishing. Thank you for your support and your feedback during our SE campaign.
If you reserved during the TTW stage this is your last chance to confirm your investment to get your bonus share, and to all the people interested in investing, here are some of the reasons why we think you should.
CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.
Delee is backed by Y Combinator, StartX, and Emles Venture Partners.
The founders have a scientific background and more than 10 years of experience developing scientific instrumentation.
Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,
Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required.
To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center.
The TAM for the use of CTCs in clinical applications is calculated at over $543B.
We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.
Thanks to all investors for believing in our vision and for making it a reality.
Delee Team 💙
04.06.22
The final 24 hours to become an investor in Delee!
The campaign is less than 24 hours away from finishing. Thank you for your support and your feedback during our SE campaign.
If you reserved during the TTW stage this is your last chance to confirm your investment to get your bonus share, and to all the people interested in investing, here are some of the reasons why we think you should.
CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.
Delee is backed by Y Combinator, StartX, and Emles Venture Partners.
The founders have a scientific background and more than 10 years of experience developing scientific instrumentation.
Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,
Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required.
To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center.
The TAM for the use of CTCs in clinical applications is calculated at over $543B.
We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.
Thanks to all investors for believing in our vision and for making it a reality.
Delee Team 💙
04.05.22
Only a day left to become an investor in Delee!
We’re close to the end of our campaign. From everyone working at Delee we would like to say that your support has been very important to all of us.
If you reserved during the TTW stage there is still time to confirm your investment to get your bonus share, and to all the people interested in investing, here are some of the reasons why we think you should.
CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.
Delee is backed by Y Combinator, StartX, and Emles Venture Partners.
The founders have a scientific background and more than 10 years of experience developing scientific instrumentation.
Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,
Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required.
To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center.
The TAM for the use of CTCs in clinical applications is calculated at over $543B.
We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.
Thanks to all investors for believing in our vision and for making it a reality.
Delee Team 💙
04.04.22
Meet the CytoCatch™ isolation platform, a powerful device for CTC isolation
Hello everyone!
Circulating tumor cells (CTCs) have attracted a significant amount of attention for their potential use as a blood-based biomarker to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment. The analysis of these cells will enable the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling. However, their heterogeneity and extremely low concentration in comparison to the other cellular components of blood, about 1–10 CTCs per billion blood cells, makes their capture extremely challenging… until now.
We have developed the CytoCatch™ isolation platform, which automatically performs the necessary steps to prepare and process the sample, capturing the contained CTCs. The CytoCatch™ isolation platform has the sensitivity to isolate a single CTC from a background of 50 billion blood cells, isolating these malignant cells by leveraging the difference in size and deformability between CTCs and blood cells. Once captured, the CytoCatch™ isolation platform executes an automated protocol to stain the collected cells with fluorescent antibodies for their further analysis, allowing the identification of the patient’s tumor biological characteristics. The fact that all these processes are fully automated increases the reliability and reproducibility of the assay by preventing human error and cell loss due to manual steps. Furthermore, the CytoCatch™ isolation platform is compatible with traditional molecular biology techniques and next generation sequencing technologies, enabling the performance of molecular analyses to assess the genetic characteristics of the captured CTCs.
We are so excited because we are only a few months away from being able to start commercializing our technology as a research use only device, for its use in research centers and pharma companies.
We want to take this opportunity to remind you that there are less than 48 hours left until Delee’s campaign ends. For those who reserved shares during the TTW stage, you only have this period of time to confirm your investment and receive your 10% bonus shares. If you haven't made an investment yet, and you’re interested, there’s still time to do so.
Thanks to everyone who supported us by becoming investors in Delee.
Delee Team 💙
04.03.22
3 days left to invest in Delee!
We’re almost reaching the end of our campaign. It has been heartwarming to know that many people believe in what we’re doing and most importantly that they believe in us.
For the people that reserved but did not confirm their investment remember that you still have this period of time to confirm and receive your bonus shares.
For our followers still on the fence about investing here is why we think you should invest in us
CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.
Delee is backed by Y Combinator, StartX, and Emles Venture Partners.
The founders have a scientific background and more than 10 years of experience developing scientific instrumentation.
Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,
Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required.
To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center.
The TAM for the use of CTCs in clinical applications is calculated at over $543B.
We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.
Thanks to everyone who supported us by becoming investors in Delee.
Delee Team 💙
04.02.22
4 days left to invest in Delee!
We’re almost reaching the end of our campaign. It has been heartwarming to know that many people believe in what we’re doing and most importantly that they believe in us.
For the people that reserved but did not confirm their investment remember that you still have this period of time to confirm and receive your bonus shares.
For our followers still on the fence about investing here is why we think you should invest in us
CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.
Delee is backed by Y Combinator, StartX, and Emles Venture Partners.
The founders have a scientific background and more than 10 years of experience developing scientific instrumentation.
Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,
Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required.
To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center.
The TAM for the use of CTCs in clinical applications is calculated at over $543B.
We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.
Thanks to everyone who supported us by becoming investors in Delee.
Delee Team 💙
04.01.22
Meet the CytoCatch™ imaging system, a powerful platform for CTC analysis
Hello everyone!
As you know, our technology is composed of two devices, the CytoCatch™ isolation platform, which processes the sample capturing the contained CTCs, and the CytoCatch™ imaging system, which performs the analysis of the captured cells. In this update we want to talk about some of the characteristics that make the CytoCatch™ imaging system an ideal platform for CTC analysis.
Once the sample has been processed, the substrate where the CTCs are captured is placed in the CytoCatch™ imaging system to enumerate CTCs and identify specific biological characteristics that give information to physicians about treatment selection and therapy response assessment. The CytoCatch™ imaging system has very unique characteristics that allow the complete mapping of the substrate area where the CTCs were captured, as shown in the video. This mapping is performed at different focal planes to ensure that all the cells are in focus, increasing the reliability of the analysis. Furthermore, the CytoCatch™ imaging system allows the fluorescence-based identification of up to 6 different markers in the captured cells, which gives the flexibility to create specific panels for a wide variety of cancers, providing valuable information to physicians regarding the identification of possible markers that serve as targets for targeted therapies. Finally, the CytoCatch™ imaging system has a powerful built-in AI that enumerates the captured CTCs and categorizes them based on their biological characteristics, thereby eliminating the subjective interpretation of operators and increasing the reproducibility of analysis, while decreasing the time needed to manually enumerate the CTCs captured.
We are so excited because we are only a few months away from being able to start commercializing our technology as a research use only device, for its use in research centers and pharma companies.
We want to take this opportunity to remind you that there are only 5 days left until Delee’s campaign ends. For those who reserved shares during the TTW stage, you only have this period of time to confirm your investment and receive your 10% bonus shares. If you haven't made an investment yet, and you’re interested, there’s still time to do so.
Thanks to everyone who supported us by becoming investors in Delee.
Delee Team 💙
04.01.22
Delee passes $300,000 in investments!
We are thrilled to announce that our campaign has passed $300k in investments, we are so happy to reach another milestone!
What we have accomplished has only been possible thanks to everyone who has joined our mission of revolutionizing cancer blood tests.
We are on the final days of our campaign, for those who reserved shares during the TTW stage, these are the last days you have to confirm your investment and receive your 10% bonus shares.
And if you haven't invested yet, you still have time to do so.
Delee Team 💙
03.31.22
1 week left to invest in Delee!
Hello everyone!
The final week of our campaign has started. To everyone that has supported us and has become an investor we would like to thank you for allowing us to continue our endeavor of helping people with cancer detection and treatment.
For those who reserved shares during the TTW stage, you still have this next week to confirm your investment and receive your 10% bonus shares.
And if you haven't invested yet, and you’re interested, you still have time to do so.
Thank you!
Delee Team 💙
REWARDS
JOIN THE DISCUSSION
0/2500
Carlos Garza Garza
2 months ago
Are there any updates? Last update was in 2023.
0
0
Alireza Khadem-Ghaeini
2 years ago
Are there any updates?
0
0
Travis Silman
2 years ago
Greetings Delee Team, I invested into your campaign on July 18th 2021 and did not get an offering for it. I invested $199.20 and was not acknowledged. I have invested in your campaign on other sites and got appreciation for it, but not on here and the date that I invested. Can you please let me know why it was not acknowledged and if I will get a refund if it wasn't? Thank you, Travis Silman
Show more
0
0
augustine Njoku
3 years ago
Can investment under TTW be increased? And does the bonus still applies ?
2
0
Miguel Costa
3 years ago
Hello Ms. Velarde, Sorry to see that the StartEngine crowdfund raise isn't going as well as expected. I have been part of both crowdfund rounds and I intend to add more on this one. Are you going to further extend this Crowdfunding round, or you are going to end it in about 2 weeks? Best regards, Miguel Costa
Show more
2
0
Titus Polichnia
3 years ago
The last round on Republic, Delee definitely had a better raise. Will 300k give Delee enough runway ?
1
0
Guenadi Jilevski
3 years ago
Is it a Qualified Small Business Stock? https://www.investopedia.com/terms/q/qsbs-qualified-small-business-stock.asp
Show more
1
0
Vineet Agarwal
3 years ago
Hello Team Delee, in the updates provided 3 days ago, you mentioned the technology is working great in the clinical trials. I am trying to understand this more objectively. Do you know how may false positives and false negatives are you observing? How are you measuring the results from the clinical trials?
Show more
1
1
Vineet Agarwal
3 years ago
Hello Team Delee I am considering investing in Delee, so have a couple of questions 1. Is this one of the patents which you have filed? If yes then this shows that it was filed in 2017, so given that it more than 4 years now, do you know what is the status on this application? https://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20200376499.PGNR. 2. Is this the only patent which has been filed or are there other patents for the device and/or consumables? Would you be able to provide a link and status for these patent applications? 3. When do you expect to start generating revenue ? Thank You! Vineet
Show more
1
1
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
FAQS
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000 are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, they are limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancellation period. Once the four-hour window has passed, it is up to each company to set their own cancellation policy. You may find the company’s cancellation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
PINNED BY STARTUP
Lanelle Schultz
4 years ago
Hello Team Delee, Just did my reserve and am super excited. I participated on Republic as well. Yesterday I was at the doctor and showed him your website he was blown away. Happy to be on this ride with you for part 2! Lanelle
Show more
1
0